Intratumoral therapies and in-situ vaccination for melanoma

Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients

(2020) A. Algazi et al.   ANNALS OF ONCOLOGY

B cells and tertiary lymphoid structures promote immunotherapy response

(2020) Beth A. Helmink et al.   NATURE

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

(2020) Alain P. Algazi et al.   CLINICAL CANCER RESEARCH

A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells

(2019) Junko Matsuzaki et al.   Journal for ImmunoTherapy of Cancer

STING Signaling in Melanoma Cells Shapes Antigenicity and Can Promote Antitumor T-cell Activity

(2019) Rana Falahat et al.   Cancer Immunology Research

Intratumoral Plasmid IL12 Electroporation Therapy in Patients with Advanced Melanoma Induces Systemic and Intratumoral T-cell Responses

(2019) Samantha K. Greaney et al.   Cancer Immunology Research

Intralesional anti-PD1 treatment in patients with metastatic melanoma: The pilot study.

(2018) Igor Samoylenko et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma

(2018) Jason Chesney et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding the tumor immune microenvironment (TIME) for effective therapy

(2018) Mikhail Binnewies et al.   NATURE MEDICINE

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments

(2018) Kevin C. Barry et al.   NATURE MEDICINE

T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model

(2018) Hao Liu et al.   PLoS One

Eradication of spontaneous malignancy by local immunotherapy

(2018) Idit Sagiv-Barfi et al.   Science Translational Medicine

Interim analysis of a randomized, open-label phase 2 study of talimogene laherparepvec (T-VEC) neoadjuvant treatment (neotx) plus surgery (surgx) vs surgx for resectable stage IIIB-IVM1a melanoma (MEL).

(2018) Robert Hans Ingemar Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

1245PDIntratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study

(2018) A Diab et al.   ANNALS OF ONCOLOGY

Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12

(2018) Christopher S. Garris et al.   IMMUNITY

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity

(2018) Kelsey E. Sivick et al.   Cell Reports

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

(2017) Paul C. Tumeh et al.   Cancer Immunology Research

Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability

(2016) Bernhard Mlecnik et al.   IMMUNITY

The host STING pathway at the interface of cancer and immunity

(2016) Leticia Corrales et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL INVESTIGATION

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I study of intratumoral ipilimumab and interleukin-2 in patients with advanced melanoma

(2016) Abhijit Ray et al.   Oncotarget

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

(2015) F. J. Kohlhapp et al.   CLINICAL CANCER RESEARCH

Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma

(2015) Douglas B Johnson et al.   Immunotherapy

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma

(2014) John F. Thompson et al.   ANNALS OF SURGICAL ONCOLOGY

Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity

(2014) Miranda L. Broz et al.   CANCER CELL

Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy

(2014) D. Zamarin et al.   Science Translational Medicine

Electrochemotherapy for disseminated superficial metastases from malignant melanoma

(2012) L. G. Campana et al.   BRITISH JOURNAL OF SURGERY

Marginating Dendritic Cells of the Tumor Microenvironment Cross-Present Tumor Antigens and Stably Engage Tumor-Specific T Cells

(2012) John J. Engelhardt et al.   CANCER CELL

Tertiary lymphoid organs in infection and autoimmunity

(2012) Katrijn Neyt et al.   TRENDS IN IMMUNOLOGY

Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up

(2010) Benjamin Weide et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate

(2009) Günther F.L. Hofbauer et al.   MELANOMA RESEARCH

Ectopic Lymph Nodes Within Human Solid Tumors

(2008) Domenico Coppola et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

(2008) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemoablation of metastatic melanoma using intralesional Rose Bengal

(2008) John F. Thompson et al.   MELANOMA RESEARCH

The tumor microenvironment and its role in promoting tumor growth

(2008) T L Whiteside   ONCOGENE